242 related articles for article (PubMed ID: 16027730)
1. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
2. Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
Starczynowski DT; Trautmann H; Pott C; Harder L; Arnold N; Africa JA; Leeman JR; Siebert R; Gilmore TD
Oncogene; 2007 Apr; 26(19):2685-94. PubMed ID: 17072339
[TBL] [Abstract][Full Text] [Related]
3. An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation.
Fan Y; Gélinas C
Oncogene; 2007 Jun; 26(27):4038-43. PubMed ID: 17173064
[TBL] [Abstract][Full Text] [Related]
4. Deletion of either C-terminal transactivation subdomain enhances the in vitro transforming activity of human transcription factor REL in chicken spleen cells.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2003 Oct; 22(44):6928-36. PubMed ID: 14534540
[TBL] [Abstract][Full Text] [Related]
5. Mutant envelope residues confer a transactivation function onto N-terminal sequences of the v-Rel oncoprotein.
Epinat JC; Kazandjian D; Harkness DD; Petros S; Dave J; White DW; Gilmore TD
Oncogene; 2000 Feb; 19(5):599-607. PubMed ID: 10698504
[TBL] [Abstract][Full Text] [Related]
6. Envelope-dependent transactivation by the retroviral oncoprotein v-Rel is required for efficient malignant transformation of chicken spleen cells.
Epinat JC; Dvorin EL; Gilmore TD
Oncogene; 2000 Jun; 19(28):3131-7. PubMed ID: 10918567
[TBL] [Abstract][Full Text] [Related]
7. The v-Rel oncoprotein increases expression from Sp1 site-containing promoters in chicken embryo fibroblasts.
Sif S; Capobianco AJ; Gilmore TD
Oncogene; 1993 Sep; 8(9):2501-9. PubMed ID: 8361761
[TBL] [Abstract][Full Text] [Related]
8. Repression of the chicken c-rel promoter by vRel in chicken embryo fibroblasts is not mediated through a consensus NF-kappa B binding site.
Capobianco AJ; Gilmore TD
Oncogene; 1991 Dec; 6(12):2203-10. PubMed ID: 1766669
[TBL] [Abstract][Full Text] [Related]
9. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel.
Gilmore TD; Cormier C; Jean-Jacques J; Gapuzan ME
Oncogene; 2001 Oct; 20(48):7098-103. PubMed ID: 11704834
[TBL] [Abstract][Full Text] [Related]
10. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
11. Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes.
Fan Y; Rayet B; Gélinas C
Oncogene; 2004 Feb; 23(5):1030-42. PubMed ID: 14647412
[TBL] [Abstract][Full Text] [Related]
12. Transformation by the vRel oncoprotein requires sequences carboxy-terminal to the Rel homology domain.
Sarkar S; Gilmore TD
Oncogene; 1993 Aug; 8(8):2245-52. PubMed ID: 8336947
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells.
Kalaitzidis D; Ok J; Sulak L; Starczynowski DT; Gilmore TD
Oncogene; 2004 Sep; 23(45):7580-7. PubMed ID: 15326488
[TBL] [Abstract][Full Text] [Related]
14. A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation.
Zurovec M; Petrenko O; Roll R; Enrietto PJ
Oncogene; 1998 Jun; 16(24):3133-42. PubMed ID: 9671392
[TBL] [Abstract][Full Text] [Related]
15. Binding of c-Rel to STAT5 target sequences in HTLV-I-transformed T cells.
Sun SC; Maggirwar SB; Harhaj EW; Uhlik M
Oncogene; 1999 Feb; 18(7):1401-9. PubMed ID: 10050877
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the rel-homology domain alter the biochemical properties of v-rel and render it transformation defective in chicken embryo fibroblasts.
Morrison LE; Boehmelt G; Enrietto PJ
Oncogene; 1992 Jun; 7(6):1137-47. PubMed ID: 1594245
[TBL] [Abstract][Full Text] [Related]
17. cRel-TD kinase: a serine/threonine kinase binding in vivo and in vitro c-Rel and phosphorylating its transactivation domain.
Fognani C; Rondi R; Romano A; Blasi F
Oncogene; 2000 Apr; 19(18):2224-32. PubMed ID: 10822372
[TBL] [Abstract][Full Text] [Related]
18. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
Nehyba J; Hrdlicková R; Bose HR
Oncogene; 1997 Jun; 14(24):2881-97. PubMed ID: 9205096
[TBL] [Abstract][Full Text] [Related]
19. The suppression of SH3BGRL is important for v-Rel-mediated transformation.
Majid SM; Liss AS; You M; Bose HR
Oncogene; 2006 Feb; 25(5):756-68. PubMed ID: 16186799
[TBL] [Abstract][Full Text] [Related]
20. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
